Demographic and other characteristics of the study cohort
| Patient . | Age . | Sex . | Disease histology . | Prior therapy (response) . | Salvage therapy (response) . | Stage at transplantation . |
|---|---|---|---|---|---|---|
| 1 | 54 | F | FCg1 | CHOP/COP (PR) | FND (PR) | II |
| 2 | 45 | F | FCg1 | CHOP | — | IV B |
| 3 | 46 | F | FCg1 | CHOP (CR) | CAE (PR) | II |
| FLU (CR) | ||||||
| 4 | 60 | M | FCg2 | CHOP (PR) | FND (CR) | CR |
| XRT (PR) | ||||||
| 5 | 58 | F | FCg1 | CHOP (PR) | Ifos/etoposide (CR) | CR |
| TC (PR) | ||||||
| XRT | ||||||
| IL-2 (PD) | ||||||
| ESHAP (PR) | ||||||
| 6 | 51 | M | FCg2 | FND/IFN (CR) | ESHAP (CR) | CR |
| 7 | 50 | F | FCg1 | CHOP/ESHAP/ | FND (CR) | CR |
| NOPP (CR) | ||||||
| 8 | 59 | M | FCg1 | CHOP-Bleo/XRT (CR) | COP (CR) | CR |
| XRT (CR) COP (CR) | ||||||
| 9 | 67 | F | FCg1 | CHOP/ESHAP/NOPP (CR) | FND (CR) | CR |
| IFN (CR) | ||||||
| Rituximab (PR) | ||||||
| Bryostatin (PD) | ||||||
| 10 | 50 | M | SLL | CHOP/ESHAP/NOPP (PR) | FC (CR) | CR |
| IFN (SD) | ||||||
| 11 | 56 | M | FCg2 | COP (CR) | CHOP/Rituxan (CR) | CR |
| 12 | 31 | F | FCg1 | 131I (CR) | FND (CR) | CR |
| 13 | 46 | M | FCg1 | CHOP (PR) | CHOP/Rituxan (PR) | III |
| TI (SD) | ||||||
| GCD (CR) | ||||||
| 14 | 56 | F | FCg2 | ASHAP/MBACOS/MINE (CR) | FND/R (PR) | IA |
| Lipsomal vincristine (PR) | ||||||
| 15 | 54 | F | FCg1 | CHOP (CR) | FND (PR) | IB |
| 16 | 58 | M | FCg1 | CVAD (CR) | R (CR) | CR |
| CHOP (PR) | ||||||
| 17 | 47 | F | SLL | CHOP (CR) | FND/R (CR) | CR |
| DHAP (PR) | ||||||
| 18 | 44 | M | FCg1 | FND (CR) | — | IIIA |
| IFN (CR) | ||||||
| 19 | 68 | M | FCg1 | CHOP (PR) | ESHAP (PR) | IIIA |
| 20 | 49 | F | FCg1 | COP (CR) | MINE (CR) | CR |
| CHOP (PR) | ||||||
| ESHAP | ||||||
| Rituximab (SD) |
| Patient . | Age . | Sex . | Disease histology . | Prior therapy (response) . | Salvage therapy (response) . | Stage at transplantation . |
|---|---|---|---|---|---|---|
| 1 | 54 | F | FCg1 | CHOP/COP (PR) | FND (PR) | II |
| 2 | 45 | F | FCg1 | CHOP | — | IV B |
| 3 | 46 | F | FCg1 | CHOP (CR) | CAE (PR) | II |
| FLU (CR) | ||||||
| 4 | 60 | M | FCg2 | CHOP (PR) | FND (CR) | CR |
| XRT (PR) | ||||||
| 5 | 58 | F | FCg1 | CHOP (PR) | Ifos/etoposide (CR) | CR |
| TC (PR) | ||||||
| XRT | ||||||
| IL-2 (PD) | ||||||
| ESHAP (PR) | ||||||
| 6 | 51 | M | FCg2 | FND/IFN (CR) | ESHAP (CR) | CR |
| 7 | 50 | F | FCg1 | CHOP/ESHAP/ | FND (CR) | CR |
| NOPP (CR) | ||||||
| 8 | 59 | M | FCg1 | CHOP-Bleo/XRT (CR) | COP (CR) | CR |
| XRT (CR) COP (CR) | ||||||
| 9 | 67 | F | FCg1 | CHOP/ESHAP/NOPP (CR) | FND (CR) | CR |
| IFN (CR) | ||||||
| Rituximab (PR) | ||||||
| Bryostatin (PD) | ||||||
| 10 | 50 | M | SLL | CHOP/ESHAP/NOPP (PR) | FC (CR) | CR |
| IFN (SD) | ||||||
| 11 | 56 | M | FCg2 | COP (CR) | CHOP/Rituxan (CR) | CR |
| 12 | 31 | F | FCg1 | 131I (CR) | FND (CR) | CR |
| 13 | 46 | M | FCg1 | CHOP (PR) | CHOP/Rituxan (PR) | III |
| TI (SD) | ||||||
| GCD (CR) | ||||||
| 14 | 56 | F | FCg2 | ASHAP/MBACOS/MINE (CR) | FND/R (PR) | IA |
| Lipsomal vincristine (PR) | ||||||
| 15 | 54 | F | FCg1 | CHOP (CR) | FND (PR) | IB |
| 16 | 58 | M | FCg1 | CVAD (CR) | R (CR) | CR |
| CHOP (PR) | ||||||
| 17 | 47 | F | SLL | CHOP (CR) | FND/R (CR) | CR |
| DHAP (PR) | ||||||
| 18 | 44 | M | FCg1 | FND (CR) | — | IIIA |
| IFN (CR) | ||||||
| 19 | 68 | M | FCg1 | CHOP (PR) | ESHAP (PR) | IIIA |
| 20 | 49 | F | FCg1 | COP (CR) | MINE (CR) | CR |
| CHOP (PR) | ||||||
| ESHAP | ||||||
| Rituximab (SD) |
F indicates female; M, male; FCg1, follicular center grade 1; FCg2, follicular center grade 2; SLL, small lymphocytic lymphoma; CAE, cyclophosphamide doxorubicin etoposide; CHOP-Bleo, cyclophosphamide doxorubicin vincristine prednisone bleomycin; FLU-fludarabine; COP, cyclophosphamide vincristine prednisone; FND, fludarabine mitoxantrone dexamethasone; HCVAD, fractionated cyclophosphamide vincristine doxorubicin dexamethasone; XRT, radiotherapy; TC, paclitaxel cyclophosphamide; IL-2, interleukin-2; VBD, vincristine bleomycin dexamethasone; ESHAP, etoposide Solu-Medrol cytarabine cisplatin, Ifos-ifosfamide; NOPP, mitoxantrone vincristine prednisone procarbazine; IFN, interferon; TI, paclitaxel ifosfamide; GCD, gemcitabine cisplatin Decadron; R, rituximab; MBACOS, methotrexate bleomycin doxorubicin cyclophosphamide vincristine Solu-Medrol; MINE, mesna ifosfamide novantrone etoposide; SD, stable disease.